New combo aims to tame hairy cell leukemia with fewer side effects
NCT ID NCT05388123
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tested a combination of two drugs—vemurafenib (taken by mouth) and rituximab (given by IV)—in 15 people with hairy cell leukemia, a rare blood cancer. The goal was to see if this treatment works as well as or better than standard chemotherapy, but with fewer side effects. Participants received a lower dose of vemurafenib than in past studies to try to reduce skin reactions and other problems.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- vemurafenib and rituximab
- What this could lead to
- If successful, this could offer a less toxic, effective treatment option for hairy cell leukemia, reducing side effects compared to standard chemotherapy.
- What could go wrong
- This is a small, early-phase pilot study with only 15 participants, so results may not apply broadly. The low-dose vemurafenib might be less effective, and side effects are still possible.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HAIRY CELL LEUKEMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Scripps Cancer Center
La Jolla, California, 92037, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a Two-Drug combo beat back Tough-to-Treat hairy cell leukemia?
- New drug duo aims to tackle rare leukemia
- New registry aims to unlock secrets of rare leukemia
- Engineered immune cells take aim at stubborn blood cancers
- New combo therapy targets rare blood cancer in early trial
- Engineered t cells take on tough leukemia and lymphoma